Feature | February 22, 2013| Dave Fornell

FDA Approves Use of Common Abbott Devices to Treat for Coronary CTOs

Additional indications allow its everyday guidewires and balloons to be used in chronic total occlusions (CTOs)

balloon, CTO

Abbott's Mini-Trek balloon dilatation catheter.

guidewire, CTO

Abbott'e HT Pilot guidewire.

February 22, 2013 — Physicians have new tools for treating coronary chronic total occlusions (CTOs) after Abbott received U.S. Food and Drug Administration (FDA) approval this week for guidewires and balloon dilation catheters for treatment of CTOs. Abbott is the only company with FDA approvals of its everyday products for treatment of CTOs.

The FDA approval is for Abbott's HT Progress and HT Pilot guidewires and Mini-Trek balloon dilatation catheter products.

Treatment of CTOs, a 100 percent blockage in the artery, continues to be a controversial topic among cardiac specialists, though estimates indicate that 15 to 20 percent of patients undergoing coronary angiography have a CTO. While some physicians believe they are benign, others believe that CTOs are a slow, silent killer. In addition, treating CTOs with minimally invasive methods is not easy. Up until now, only a handful of specialty CTO products were approved to tackle these lesions.

While the recommended treatment for CTOs varies widely among doctors, many say coronary CTOs offer a potential growth area for patient volume in cath labs. Clinical evidence supports the treatment of CTOs if good procedural outcomes can be obtained. Patients with CTOs can experience significant improvements in quality of life if blood flow is restored to the vessel.

Clearly navigating CTOs can be difficult under 2-D angiography, which only shows a lumengram in the parts of the vessel that are not blocked. The controversy over treating CTOs often involves the guesswork involved when attempting to push wires through the occlusion without piercing the wall of the artery. However, recent advances in 3-D rotational angiography and fusion imaging with these images or computed tomography (CT) or magnetic resonance imaging (MRI) 3-D vessel reconstructions overlaid on live fluoroscopy are expected to greatly aid these types of procedures.

For more information: www.abbottvascular.com





Related Content

coherex Wave Crest LAA Occluder

Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.

News | November 24, 2015
November 24, 2015 — Biosense Webster announced it has acquired Coherex Medical Inc., a privately held medical device
Feature | Cath Lab| November 24, 2015
November 24, 2015 — The U.S.
Boston Scientific, Watchman FLX, LAA closure device, CE mark, first European implants

Image courtesy of Boston Scientific

News | Left Atrial Appendage (LAA) Occluders| November 20, 2015
Boston Scientific announced the first implants of the Watchman FLX left atrial appendage closure (LAAC) device
News | Cath Lab| November 10, 2015
TherOx Inc. announced it has received U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE)...
Sponsored Content | Videos | TCT| November 05, 2015
Tom Watson, clinical analyst for MDBuyLine, and DAIC Dave Fornell discuss some of the technology trends at the 2015 T
Sponsored Content | Videos | TCT| November 05, 2015
DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies pr
CSI, OPTIMIZE study, peripheral orbital atherectomy system, peripheral artery disease, PAD

Diamondback 360 orbital atherectomy system. Image courtesy of Cardiovascular Systems Inc.

News | Atherectomy Devices| November 03, 2015
Cardiovascular Systems Inc. (CSI) announced last week that the first two patients have been enrolled in its OPTIMIZE,...
Sponsored Content | Videos | Cath Lab| November 03, 2015
Guillaume Baillaird, CEO of ControlRad Systems, described how his company's technology can significantly reduce radia
Overlay Init